Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — FY2014 Earnings Presentation

27 slides from Sucampo Pharmaceuticals's earnings presentation, Mar 4, 2015

  1. Slide 1: Fourth Quarter and Full Year 2014 Corporate Update and Financial Results

    Fourth Quarter and Full Year 2014 Corporate Update and Financial Results March 4, 2015 $ sucamPo The Science of Innovation

  2. Slide 2: Silvia Taylor, Senior Vice President, Investor Relations

    Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications é 3 SUCAMPO The Science of Innovation

  3. Slide 3: Agenda

    Agenda Introductions and Forward-Looking onan Silvia Taylor Statements Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Performance Andrew Smith Closing Remarks Peter Greenleaf $ sucampo 3 The Science of Innovation

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ m

  5. Slide 5: Full Year 2014 Corporate Update

    id Full Year-2014 Corporate Peter Greenleaf Chief Executive Officer @ 3 SUCAMPO The Science of Innovation

  6. Slide 6: 2014 Key Highlights

    2014 Key Highlights 1. Continued strong financial performance 2. Significant progress in securing AMITIZA growth 3. Focused our efforts and added organizational capabilities 4. Focused on driving pipeline development $ sucampo 8 The Science of innovation as

  7. Slide 7: Continued Strong Financial Performance

    Continued Strong Financial Performance Significant gains drove strong financial performance in 4Q + Overall revenue grew 54% + Product royalty revenue from U.S. sales of AMITIZA grew 25% + Product sales revenue of AMITIZA from Japan grew 44% FY 2014 reported net income and EPS + GAAP net income was

  8. Slide 8: U.S. AMITIZA Performance

    U.S. AMITIZA Performance Sucampo AMITIZA revenue + 4Q royalty revenue grew 25% to $18.6M + FY 2014 grew 21% to $62.8M Takeda AMITIZA net sales + 4Q increased 17% to $91.1M* + FY 2014 increased 18% to $331.6M* AMITIZA total prescriptions + 4Q grew 5% YoY; strongest quarter ever FY 2014 grew 4.2% YoY;

  9. Slide 9: Improving and Strengthening Partnerships

    Improving and Strengthening Partnerships Strengthened partnership with Takeda + Signed a global license, development, commercialization and supply agreement for AMITIZA for all global markets except Japan and China + Amended our existing collaboration and license agreement covering North America * S

  10. Slide 10: New Market Opportunities

    New Market Opportunities Global prevalence of constipation disorders ranges from 5-18% U.K. a 3 en, cle; 1 ot Eu. i 7 _ Canada OlCunder fi cic i # ClCandOlc i irae : 4 NDA decision "seansnosnnsnesnesensneressnsnnet rae 2H:15 + Necseroesnsennsaaemnaneenens a sa ; pai nce 1 Switzerland i us. q CIC and

  11. Slide 11: Japan AMITIZA Performance

    Japan AMITIZA Performance Sucampo AMITIZA revenue * 4Q sales grew 44% to $7.4M + FY 2014 grew 103% to $32.1M Abbott AMITIZA net sales performance + December 2014 strongest month of sales + 1B yen ($8.9M) in Abbott net sales + 8M capsules dispensed * 4Q YoY growth * 31% growth Recently Mylan acquired

  12. Slide 12: IP Update

    IP Update Received a Paragraph IV notice letter regarding an ANDA submitted by Dr. Reddy’s Laboratories + Will continue to vigorously defend IP of AMITIZA Entered into an additional settlement with Par for a generic version of RESCULA $ sucampo 2 The Science of Innovation as

  13. Slide 13: Board & Management Update

    Board & Management Update Two Additional Board Members John Johnson: held numerous executive management roles at leading global pharmaceutical corporations + Robert Spiegel: currently CMO of PTC Therapeutics; involved in the successful filing of 30+ New Drug Applications New CFO Named Andrew Smith,

  14. Slide 14: Peter Kiener, D. Phil, Chief Scientific Officer

    Peter Kiener, D. Phil Chief Scientific Officer ¢ ‘ 3 SUCAMPO ki The Science of Innovation

  15. Slide 15: At-A-Glance: Sucampo Pipeline

    At-A-Glance: Sucampo Pipeline : CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS a ESSE SS EE EE ee es Lubiprostone — Pediatric Functional Phvotat ‘Opentabel Constipation (6 years.17 years) Lpimzuzo1s Le -242015 Fel—2H ane LPI=2H 2015 Lubiprostone ~New Formulation ~Pediatric ‘Open-Labet

  16. Slide 16: Diversify Our Science and Portfolio

    Diversify Our Science and Portfolio Ongoing assessment of new therapeutic areas and targets, both early and mid-to-late stage + Started in our core capabilities of ophthalmology and gastroenterology + Will evaluate attractive assets in other therapeutic areas which could add value $ sucampo 16 The S

  17. Slide 17: Full Year 2014 Performance

    Full Year 2014 Performance Andrew Smith Chief Financial Officer € 7 3 SUCAMPO : The Science of Innovation

  18. Slide 18: Revenue Highlights ($M)

    le Highlights ($M) a $37.8 —! Q4-13 Q4-14 Q4-13 Q4-14 Q413 4-14 Total Revenue Product Royalty Product Sales Revenue Revenue ¢ 18 Recognized $8.0M of the $14.0M of the upfront payment in@4:14 4 SUCAMPO ‘on twnnvene

  19. Slide 19: Financial Performance ($M, GAAP Earnings)

    Financial Performance ($M, GAAP Earnings) $13.1 $0.29 Q4-14 -YTD-14 Q4-14 YTD-14 Net Income EPS $ sucampo 19 The Science of Innovation

  20. Slide 20: Financial Performance ($M, Excluding Special Items)

    ncial Performance($M,Excluding,Special $0.40 $17.9 YTD-14 Oo YTD-14 Net Income EPS $ sucampo 20 The Science of Innovation

  21. Slide 21: Expense Highlights ($M)

    se Highlights ($M) $7.7 Q4-13 Q4-14 Q4-13 Q4-14 Q4-13 Q4-14 Q4-13 Q4-14 Cost of Goods Sold R&D Expenses G&A Expenses S&M Expenses $ sucampo 2 The Science of Innovation

  22. Slide 22: Cash, Cash Equivalents, Restricted Cash and Investments $110.0M

    Cash, Cash Equivalents, Restricted Cash and Investments $110.0M Notes Payable $25.8M 5 SUCAMPO a The Science of Innovation

  23. Slide 23: 2015 Guidance: Net Income $25 - $30M

    Net Income $25 - $30M EPS $0.55 - $0.65 g SUCAMPO = OP Ine Science of innovation

  24. Slide 24: Peter Greenleaf, Chief Executive Officer

    Peter Greenleaf Chief Executive Officer @ 24 ? SUCAMPO The Science of Innovation

  25. Slide 25: Delivered on Expectations for Quarter and Year

    Delivered on Expectations for Quarter and Year vy We have achieved strong financial performance Y_ Rapid and meaningful execution on our strategy — unlocking value ¥Y Built a world-class management team and Board $ sucampo 25 The Science of Innovation

  26. Slide 26: 2015 Priorities

    2015 Priorities 1. Continued revenue growth and performance of AMITIZA 2. Focus on and delivery of our pipeline 3. Diversification of our science through deal-making 4. Addressing our capital structure $ sucampo 26 The Science of innovation

  27. Slide 27: é SUCAMPO ad

    é 9 SUCAMPO ad The Science of Innovation

Sucampo Pharmaceuticals — FY2014 Earnings Presentation on 6ix